{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.39","value":"27.4"},{"groupId":"OG001","spread":"48.3","value":"259"}]}],"title":"INCB099280 alone"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.9","value":"76.6"},{"groupId":"OG001","spread":"80.3","value":"902"}]}],"title":"INCB099280 administered with adagrasib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"During the lead-in period, INCB099280 was administered as monotherapy. During the treatment period, INCB099280 and adagrasib were coadministered. Cmax was defined as the maximum plasma concentration of INCB099280. Lead-in Period: Day -1 and Cycle 1 Day 8: predose and 0.5, 1, 2, 3, 4, 6, 8, and 12 hours postdose; predose on Day 1 of Cycles 1, 2, 4, 6, 8, 12, and every fourth cycle thereafter. Without Lead-in Period: Cycle 1 Day 8: predose and 1, 2, and 4 hours postdose; predose on Day 1 of Cycles 1, 2, 4, 6, 8, 12, and every fourth cycle thereafter.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received INCB099280 50 milligrams (mg) once daily (QD) plus adagrasib 400 mg twice daily (BID) for up to 2 years.","id":"OG000","title":"INCB099280 50 mg QD Plus Adagrasib 400 mg BID"},{"description":"Participants received INCB099280 100 mg BID plus adagrasib 400 mg BID for up to 2 years.","id":"OG001","title":"INCB099280 100 mg BID Plus Adagrasib 400 mg BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK)-Evaluable Population: all participants who received at least 1 dose of INCB099280 and provided at least 1 postbaseline plasma sample (1 PK measurement)","reportingStatus":"POSTED","timeFrame":"Day -1; Cycle 1 Day 8; Day 1 of Cycles 1, 2, 4, 6, 8, 12, and every fourth cycle thereafter","title":"Cmax of INCB099280 When Administered Alone and in Combination With Adagrasib","type":"SECONDARY","unitOfMeasure":"nanomoles per liter (nmol/L)"}